BioCardia, Inc. (BCDA) Earnings Signals & AI Vibe Check
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for BioCardia, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, BioCardia, Inc.'s filing signal
continuing negative.
earningsVibe SuperAnalyst™ Verdict:
CONTINUING NEGATIVE
Signal Performance — Stock Price Since Filing
30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Continuing Negative
GEMINI
Continuing Negative
CLAUDE
Turned Negative
CHATGPT
Continuing Negative
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does BioCardia, Inc. actually do?
Answer:
BioCardia, Inc. is a clinical-stage biotherapeutic company focused on developing cellular therapies for cardiovascular and pulmonary diseases. The company is advancing its CardiAMP(R) autologous mononuclear cell therapy platform for ischemic heart failure with reduced ejection fraction (HFrEF) and chronic myocardial ischemia (CMI), and its allogeneic mesenchymal stem cell (MSC) therapy platform for HFrEF and acute respiratory distress syndrome (ARDS). These cardiac therapies are delivered using the HelixTM transendocardial biotherapeutic delivery system, enabling minimally invasive, catheter-based intramyocardial delivery. BioCardia is pursuing regulatory approvals in the U.S. and Japan for its lead indications, with ongoing Phase III trials for HFrEF and chronic myocardial ischemia.
Question:
What are BioCardia, Inc.'s revenue drivers?
Answer:
Revenues are currently derived from biotherapeutic delivery partnering agreements, where BioCardia provides its Helix delivery system and support for partners' clinical trials. The company also generates modest revenue from its FDA-cleared AVANCE and Morph DNA steerable introducer products.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required